Amikacin – Injection Products
Recognized Interpretive Criteria
FDA Identified Interpretive Criteria
|
Minimum Inhibitory Concentrations |
Disk Diffusion |
||||
---|---|---|---|---|---|---|
Pathogen |
S |
I |
R |
S |
I |
R |
Enterobacterales |
≤ 16 |
32 |
≥ 64 |
≥ 17 |
15 – 16 |
≤ 14 |
Pseudomonas aeruginosa |
≤ 16 |
32 |
≥ 64 |
≥ 17 |
15 – 16 |
≤ 14 |
Acinetobacter spp. |
M100 standard is recognized |
|||||
Other non-Enterobacterales |
M100 standard is recognized |
- |
- |
- |
||
Staphylococcus aureus |
≤ 16 |
32 |
≥ 64 |
≥ 17 |
15-16 |
≤ 14 |
S = Susceptible; I = Intermediate; R = Resistant